Oxurion NV: Oxurion Provides Update on Clinical Pipeline Progress

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment

Related Keywords

Boston ,Massachusetts ,United States ,Nevada ,Leuven ,Region Flamande ,Belgium ,Reno ,Tom Graney ,Michael Dillen ,Arshadm Khanani ,Sylvie Berrebi Frazer Hall ,Christopher Brinzey ,Company Annual ,Clinical Research At Sierra Eye Associates ,Completed Patient Enrollment ,Diabetic Macular Edema ,Protocol Amendment ,Euronext Brussels ,Patient Enrollment ,Age Related Macular Degeneration ,Retinal Vein Occlusion ,Chief Executive Officer ,Review Board ,Best Corrected Vision ,Clinical Research ,Sierra Eye Associates ,Oxurion ,Rovides ,Update ,Linical ,Pipeline ,Progress ,